Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis

Sherri Huang; Aryanna Jordan; Dakota Jenneman; Michael Shafique; Bjorn Holmstrom

doi:10.7759/cureus.22295

Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis

Cureus. 2022 Feb 16;14(2):e22295. doi: 10.7759/cureus.22295. eCollection 2022 Feb.

Authors

Sherri Huang¹, Aryanna Jordan², Dakota Jenneman³, Michael Shafique⁴, Bjorn Holmstrom⁵

Affiliations

¹ Internal Medicine and Pediatrics, University of South Florida Morsani College of Medicine, Tampa, USA.
² Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, USA.
³ Oncology, Levine Cancer Institute, Carolinas Medical Center, Tampa, USA.
⁴ Medical Oncology, Moffitt Cancer Center, Tampa, USA.
⁵ Internal Medicine, Moffitt Cancer Center, Tampa, USA.

Abstract

Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids continue to be the mainstay of treatment for IRAEs. Here we report one of the first cases of using infliximab to treat durvalumab-associated pneumonitis.

Keywords: cancer immunotherapy; drug induced pneumonitis; immune-related adverse event (irae); infliximab; non-small cell lung carcinoma (nsclc).

Publication types

Case Reports